KR102660778B1 - Method for extracting fucoidan for glycemic control from seaweed - Google Patents
Method for extracting fucoidan for glycemic control from seaweed Download PDFInfo
- Publication number
- KR102660778B1 KR102660778B1 KR1020210021101A KR20210021101A KR102660778B1 KR 102660778 B1 KR102660778 B1 KR 102660778B1 KR 1020210021101 A KR1020210021101 A KR 1020210021101A KR 20210021101 A KR20210021101 A KR 20210021101A KR 102660778 B1 KR102660778 B1 KR 102660778B1
- Authority
- KR
- South Korea
- Prior art keywords
- seaweed
- fucoidan
- blood sugar
- extract
- present
- Prior art date
Links
- 229920000855 Fucoidan Polymers 0.000 title claims abstract description 126
- 241001474374 Blennius Species 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000002641 glycemic effect Effects 0.000 title 1
- 235000000346 sugar Nutrition 0.000 claims abstract description 32
- 239000008280 blood Substances 0.000 claims abstract description 28
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 25
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000000284 extract Substances 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 41
- 238000000746 purification Methods 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 25
- 229910001385 heavy metal Inorganic materials 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 25
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 23
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 20
- 240000002657 Thymus vulgaris Species 0.000 claims description 19
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 19
- 239000001585 thymus vulgaris Substances 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 159000000007 calcium salts Chemical class 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 238000001179 sorption measurement Methods 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 14
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 240000008886 Ceratonia siliqua Species 0.000 claims description 12
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 12
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims description 11
- 229920001543 Laminarin Polymers 0.000 claims description 11
- 239000005717 Laminarin Substances 0.000 claims description 11
- 230000001376 precipitating effect Effects 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 241001290610 Abildgaardia Species 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 238000011033 desalting Methods 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 6
- 239000012258 stirred mixture Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241001500862 Carex nubigena Species 0.000 claims description 3
- 206010011878 Deafness Diseases 0.000 claims description 3
- 235000017367 Guainella Nutrition 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000010956 nickel silver Substances 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 67
- 229920000615 alginic acid Polymers 0.000 description 29
- 235000010443 alginic acid Nutrition 0.000 description 28
- 229920001282 polysaccharide Polymers 0.000 description 27
- 239000005017 polysaccharide Substances 0.000 description 27
- 150000004804 polysaccharides Chemical class 0.000 description 25
- 239000000783 alginic acid Substances 0.000 description 20
- 229960001126 alginic acid Drugs 0.000 description 20
- 150000004781 alginic acids Chemical class 0.000 description 20
- 238000003809 water extraction Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 241000199919 Phaeophyceae Species 0.000 description 15
- 239000002904 solvent Substances 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 229940072056 alginate Drugs 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 8
- 229910052785 arsenic Inorganic materials 0.000 description 8
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 238000010306 acid treatment Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000002386 leaching Methods 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 101150024599 BSC6 gene Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- -1 polysaccharide sulfate Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 238000011085 pressure filtration Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000006001 Thymus serpyllum Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 102000004139 alpha-Amylases Human genes 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 229940024171 alpha-amylase Drugs 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 101150079307 BSC3 gene Proteins 0.000 description 2
- 101150088706 BSC5 gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 244000301850 Cupressus sempervirens Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 241000206581 Gracilaria Species 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 108091006621 SLC12A1 Proteins 0.000 description 2
- 108091006620 SLC12A2 Proteins 0.000 description 2
- 101100437897 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BSC4 gene Proteins 0.000 description 2
- 241000195474 Sargassum Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000005158 Thymus praecox ssp. arcticus Nutrition 0.000 description 2
- 235000004054 Thymus serpyllum Nutrition 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001270 Allium sibiricum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 241000037488 Coccoloba pubescens Species 0.000 description 1
- 241000234646 Cyperaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000212297 Pelvetia Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 241000195473 Sargassum fulvellum Species 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000333599 Silvetia siliquosa Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000017715 Thymus pulegioides Nutrition 0.000 description 1
- 241001184553 Thymus x citriodorus Species 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940007062 eucalyptus extract Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000004730 pulsed amperometry Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법에 관한 것으로, 해조류에서 추출된 후코이단의 함유량을 높일 수 있는 추출방법을 통해, 추출 조건을 최적화하고, 후코이단의 추출 비용 및 시간을 절감하여 대량 추출이 가능한 동시에, 초기 전분분해효소의 활성을 조절함으로써 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법을 제공하는 것이다.The present invention relates to a method of extracting fucoidan, which is capable of controlling blood sugar levels, from seaweed. The present invention relates to a method of extracting fucoidan from seaweed, optimizing extraction conditions through an extraction method that can increase the content of fucoidan extracted from seaweed, and reducing the extraction cost and time of fucoidan in large quantities. The aim is to provide a method of extracting fucoidan from seaweed, which can be extracted and at the same time can control blood sugar levels by controlling the activity of the initial starch-degrading enzyme.
Description
본 발명은 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법에 관한 것이다. 보다 상세하게는 해조류에서 추출된 후코이단의 함유량을 높일 수 있는 후코이단 추출방법을 통해, 추출 조건을 최적화하고, 후코이단의 추출 비용 및 시간을 절감하여 대량 추출이 가능한 동시에, 초기 전분분해효소의 활성을 조절함으로써 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법을 제공하기 위한 것이다.The present invention relates to a method of extracting fucoidan, which is capable of controlling blood sugar levels, from seaweed. More specifically, through a fucoidan extraction method that can increase the content of fucoidan extracted from seaweed, extraction conditions are optimized, the extraction cost and time of fucoidan are reduced, enabling mass extraction, while controlling the activity of the initial starch degrading enzyme. The purpose is to provide a method of extracting fucoidan, which can control blood sugar levels, from seaweed.
우리나라에서는 오래전부터 해조류를 식용으로 이용하고 있었으나, 해상 동물처럼 광범위하지는 못하였다. 하지만 최근 들어 해조류가 함유하고 있는 폴리페놀 계열의 영양성분, 비타민, 식물성 단백질, 미네랄 등으로, 미국에서는 차세대 슈퍼푸드 중 하나로 각광받고 있다. 또한 최근 웰빙 바람에 편승되어 해조류에 대한 영양성분 연구가 아주 활발하게 진행되고 있는 상황이다.In Korea, seaweed has been used as food for a long time, but not as widely as marine animals. However, recently, seaweed has been receiving attention as one of the next-generation superfoods in the United States due to the polyphenol-based nutrients, vitamins, vegetable proteins, and minerals it contains. In addition, thanks to the recent wellness trend, research on the nutritional properties of seaweed is being actively conducted.
해양에는 지구상 모든 생물종의 약 80%가 서식하고 있고, 막대한 자원량이 보고되고 있다. 또한 해양의 환경은 고염, 고압 및 저산소 등 육상과 매우 다르기 때문에, 해양에 서식하고 있는 해양생물은 물질대사 결과 생성될 수 있는 세포내 구성성분이 육상생물과 크게 다를 것으로 예견되고 있다. 따라서 해양생물로부터 기능성물질을 탐색하고, 이를 식품 및 식품첨가제로 이용하고자 하는 연구가 활발하게 수행되고 있으며, 시장성은 급속하게 증가하고 있는 추세이다.Approximately 80% of all species on Earth live in the ocean, and a huge amount of resources are reported. In addition, because the marine environment is very different from land, such as high salt, high pressure, and low oxygen, the intracellular components of marine organisms living in the ocean that can be produced as a result of metabolism are expected to be significantly different from those of terrestrial organisms. Therefore, research to discover functional substances from marine organisms and use them as food and food additives is being actively conducted, and marketability is rapidly increasing.
또한, 해조류는 오래 전부터 우리나라를 비롯한 주변 아시아 국가들에서 섭취되어 왔으나, 최근 해조류의 중금속 제거활성, 항고혈압 활성, 고지혈증 예방, 항암 활성, 항염증, 항산화 활성, 항균 활성 등의 잠재적인 건강증진 효과들이 알려지면서 유럽에서도 해조를 단순한 기능성 식품 및 의약품의 원료로 사용하는 것에 그치지 않고, 음식으로 직접 섭취하는 등의 적극적인 변화를 보이고 있다.In addition, seaweed has been consumed in Korea and neighboring Asian countries for a long time, but recently, seaweed's potential health promotion effects such as heavy metal removal activity, antihypertensive activity, hyperlipidemia prevention, anticancer activity, anti-inflammatory, antioxidant activity, and antibacterial activity have been discovered. As they become known, Europe is also showing active changes such as not only using seaweed as a raw material for functional foods and medicines, but also consuming it directly as food.
해조류는 대부분 수분으로 이루어져 있고, 나머지 성분 중 탄수화물이 가장 많아 당질이 전체 물량 기준으로 거의 절반 이상 된다. 이러한 해조류의 주요 성분인 다당류는 바깥층에서 미세한 섬유상의 결정 구조인 세포벽 다당, 이를 덮고 있는 무정형 겔 상태의 점질다당, 세포 안에 있는 저장 다당, 세 가지로 나눌 수 있다.Seaweed consists mostly of water, and has the highest carbohydrate content among the remaining ingredients, making up almost half of the total amount of carbohydrates. Polysaccharides, which are the main components of these seaweeds, can be divided into three types: cell wall polysaccharides, which have a fine fibrous crystal structure in the outer layer, amorphous gel-like viscous polysaccharides that cover them, and storage polysaccharides within the cells.
해조류는 크게 녹조, 갈조, 홍조로 분류되며, 종류에 따라 그 구성성분은 조금씩 다르다. 이러한 다당류의 유용성은 다음과 같다. 약리효과로는 혈액응고방지, 혈중 중성지질 감소(해조 황산다당, 후코이단, 카라기난, 사라가산), 항콜레스테롤효과(해조 산성다당), 항암효과(칼조류의 황산다당, 청각, 후코이단), 영양효과 (가용성 식이섬유소), 에너지자원(바이오매스), 해조바이오테크놀로지(헤조 다당 분해효소 이용 프로토플라스트 제조) 등이 있다.Seaweed is broadly classified into green algae, brown algae, and red algae, and its composition varies slightly depending on the type. The usefulness of these polysaccharides is as follows: Pharmacological effects include prevention of blood coagulation, reduction of neutral lipids in the blood (seaweed polysaccharide sulfate, fucoidan, carrageenan, saragasic acid), anti-cholesterol effect (seaweed acid polysaccharide), anti-cancer effect (sulfate polysaccharide of sword algae, chives, fucoidan), and nutritional effects. (soluble dietary fiber), energy resources (biomass), and seaweed biotechnology (protoplast production using hezopolysaccharide degrading enzyme).
이중 갈조류는 수분과 다당 외 여러 무기질로 구성되어 있으며 다당류 성분은 세포벽다당의 직쇄 글루칸, 점질다당(해조 특유 다당, 알긴산, 후코이단, sargassan), 저장다당(라미나린) 등과 같다. 특히 알긴산은 Na-알기네이트 식품첨가물, 섬유(일진산레이온), 아이스크림, 치즈안정제, 의약용 거즈, 다이어트식품(Sr, Cd 체내 흡억제, 정장작용, 무칼로리)에 이용되고 있다.Among them, brown algae are composed of various minerals in addition to water and polysaccharides, and the polysaccharide components include straight-chain glucans of cell wall polysaccharides, viscous polysaccharides (polysaccharides unique to seaweeds, alginic acid, fucoidan, sargassan), and storage polysaccharides (laminarin). In particular, alginic acid is used as Na-alginate food additive, fiber (Iljinsan rayon), ice cream, cheese stabilizer, medical gauze, and diet food (Sr, Cd absorption inhibition, intestinal function, calorie-free).
그 외 갈조류가 포함하고 있는 무기질 성분으로 칼슘, 칼륨, 마그네슘, 요오드, 철, 아연 등이 있으며 이는 제5의 영양소라고 알려질 정도로 인체 및 동물의 성장이나 각종 질병의 예방에 탁월한 효능이 있는 것으로 알려지고 있다.Other minerals contained in brown algae include calcium, potassium, magnesium, iodine, iron, and zinc, which are known to be excellent for the growth of humans and animals and the prevention of various diseases, to the extent that they are known as the fifth nutrient. there is.
해조는 여러 가지 유용물질을 포함하고 있으나, 이중 특히 주목할 것이 후코이단과 무기질 성분이다.Seaweed contains various useful substances, but fucoidan and mineral components are especially noteworthy.
특히, 한국과 일본 및 중국의 동아시아에서 오랜 기간 섭취하여 온 미역과 다시마 등의 갈조류에 함유된 고분자 다당체인 후코이단(fucoidan)이 발현하는 여러 가지의 기능성에 대한 관심이 증폭되고 있다.In particular, interest in the various functionalities expressed by fucoidan, a high molecular weight polysaccharide contained in brown algae such as seaweed and kelp, which have been consumed for a long time in East Asia such as Korea, Japan, and China, is growing.
후코이단(fucoidan)은 해조류에 존재하는 후코오즈(fucose)를 주성분으로 황산기를 함유하고 있는 다당류로서, 일반적으로 다시마, 미역, 톳 등과 같은 갈조류에 다량 존재한다. 이러한 후코이단은 혈행 개선, 항암 등 생리적 활성이 우수할 뿐만 아니라 미백, 보습, 주름개선 등의 효과가 있는 것으로 알려져 화장품 원료로서도 각광받고 있다.Fucoidan is a polysaccharide containing sulfate groups with fucose present in seaweed as its main ingredient, and is generally present in large quantities in brown algae such as kelp, seaweed, and hijiki. Fucoidan is known to have excellent physiological activities such as improving blood circulation and anti-cancer, as well as having whitening, moisturizing, and wrinkle-improving effects, so it is also in the spotlight as a cosmetic raw material.
또한, 후코이단은 L-푸코오스를 주성분으로 하고 다수의 황산기를 함유하는 다당류로서 다시마, 미역, 톳 등의 갈조류에 다량 함유되어 있다. 후코이단의 화학적 구조, 생리활성, 분자량 등은 갈조류의 종류, 수확장소, 수확시기 등에 따라 달라진다.In addition, fucoidan is a polysaccharide whose main component is L-fucose and contains a large number of sulfate groups, and is contained in large quantities in brown algae such as kelp, seaweed, and hijiki. The chemical structure, physiological activity, and molecular weight of fucoidan vary depending on the type of brown algae, harvest location, and harvest time.
후코이단은 면역 활성 증진, 항 혈액응고 효과, 항산화 효과, 항암효과, 항균효과 등의 다양한 생리활성을 나타내며, 이러한 효과를 바탕으로 의약품, 화장품, 식품 산업 등에 적용하고자 하는 연구들이 활발히 진행되고 있다.Fucoidan exhibits various physiological activities such as enhancing immune activity, anti-coagulant effect, antioxidant effect, anticancer effect, and antibacterial effect, and based on these effects, research is being actively conducted to apply it to the pharmaceutical, cosmetics, and food industries.
이러한 해조류 중에 포함된 여러 가지 유용한 성분 추출을 위하여 다양한 추출방법이 시도되고 있으나, 대부분 물리적 조작이나 산 분해를 통해 추출하기 때문에 환경오염문제를 유발하고 작업자의 건강을 위협할 뿐 아니라 추출 공정에 많은 비용이 소요되는 단점이 있다.Various extraction methods have been attempted to extract various useful ingredients contained in these seaweeds, but most are extracted through physical manipulation or acid decomposition, which not only causes environmental pollution problems and threatens the health of workers, but also causes high costs in the extraction process. There is a downside to this.
본 발명의 목적은 해조류에서 추출된 후코이단의 함유량을 높일 수 있는 후코이단 추출방법을 통해, 추출 조건을 최적화하고, 후코이단의 추출 비용 및 시간을 절감하여 대량 추출이 가능한 후코이단 추출방법을 제공하기 위한 것이다.The purpose of the present invention is to provide a fucoidan extraction method that can increase the content of fucoidan extracted from seaweed, optimize extraction conditions, reduce fucoidan extraction cost and time, and enable mass extraction of fucoidan.
본 발명의 다른 목적은 초기 전분분해효소의 활성을 조절함으로써 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법을 제공하기 위한 것이다.Another object of the present invention is to provide a method of extracting fucoidan, which is capable of controlling blood sugar levels, from seaweed by controlling the activity of the initial starch-degrading enzyme.
본 발명의 일 실시예에 따른 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법은 1) 해조류를 건조 및 탈염시키는 전처리 단계; 2) 상기 1) 단계의 전처리된 해조류를 칼슘염 수용액과 혼합하는 혼합단계; 3) 상기 2) 단계의 교반된 혼합물을 원심분리시켜 감압 여과하는 제1 정제 단계; 4) 상기 3) 단계의 여과된 혼합물을 알코올 용액에 침전시키는 단계; 5) 상기 4) 단계의 침전물을 원심분리시켜 상등액을 수득하는 제2 정제 단계; 6) 상기 5) 단계의 상등액을 알코올 용액에 침전시키는 단계; 7) 상기 6) 단계의 침전물을 원심분리시켜 상등액을 제거하는 제3 정제 단계; 및 8) 상기 7) 단계의 상등액이 제거되고 남은 침전물을 건조시켜 후코이단(Fucoidan)을 획득하는 단계를 포함한다.A method of extracting fucoidan, which is capable of controlling blood sugar levels, from seaweed according to an embodiment of the present invention includes 1) a pretreatment step of drying and desalting seaweed; 2) a mixing step of mixing the seaweed pretreated in step 1) with an aqueous calcium salt solution; 3) a first purification step of centrifuging the stirred mixture of step 2) and filtering it under reduced pressure; 4) precipitating the filtered mixture of step 3) in an alcohol solution; 5) a second purification step of centrifuging the precipitate from step 4) to obtain a supernatant; 6) Precipitating the supernatant of step 5) in an alcohol solution; 7) a third purification step of centrifuging the precipitate from step 6) to remove the supernatant; and 8) removing the supernatant of step 7) and drying the remaining precipitate to obtain Fucoidan.
상기 칼슘염 수용액은 염화칼슘(CaCl2) 수용액, 탄산칼슘(CaCO3) 수용액, 수산화칼슘(Ca(OH)2) 및 이들의 혼합으로 이루어진 군으로부터 선택되는 것이다.The calcium salt aqueous solution is selected from the group consisting of calcium chloride (CaCl 2 ) aqueous solution, calcium carbonate (CaCO 3 ) aqueous solution, calcium hydroxide (Ca(OH) 2 ), and mixtures thereof.
상기 해조류는 미역귀, 톳, 모자반, 다시마, 꼬시래기, 뜸부기 및 이들의 혼합으로 이루어진 군으로부터 선택되는 것이다.The seaweed is selected from the group consisting of seaweed, hijiki, kelp, kelp, seaweed, seaweed, and mixtures thereof.
상기 후코이단(Fucoidan)은 600 내지 900KDa의 분자량을 나타내는 것이다.The fucoidan has a molecular weight of 600 to 900 KDa.
상기 후코이단(Fucoidan)은 전분분해효소 저해능을 통해, 혈당 조절 효과를 나타내는 것으로, 상기 전분분해효소는 알파-글루코시다제(α-glucosidase)를 포함하는 것이다.The fucoidan exhibits a blood sugar control effect through its ability to inhibit starch-degrading enzymes, and the starch-degrading enzyme includes alpha-glucosidase.
본 발명의 다른 일 실시예에 따른 당뇨병 예방 및 개선용 식품 조성물은 상기 방법에 따라 추출된 후코이단을 포함하여 제조되는 것이다.A food composition for preventing and improving diabetes according to another embodiment of the present invention is manufactured including fucoidan extracted according to the above method.
본 발명의 다른 일 실시예에 따른 당뇨병 예방 및 치료용 약학 조성물은 상기 방법에 따라 추출된 후코이단을 포함하여 제조되는 것이다.A pharmaceutical composition for preventing and treating diabetes according to another embodiment of the present invention is prepared including fucoidan extracted according to the above method.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 실시예에 따른 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법은 1) 해조류를 건조 및 탈염시키는 전처리 단계; 2) 상기 1) 단계의 전처리된 해조류를 칼슘염 수용액과 혼합하는 혼합단계; 3) 상기 2) 단계의 교반된 혼합물을 원심분리시켜 감압 여과하는 제1 정제 단계; 4) 상기 3) 단계의 여과된 혼합물을 알코올 용액에 침전시키는 단계; 5) 상기 4) 단계의 침전물을 원심분리시켜 상등액을 수득하는 제2 정제 단계; 6) 상기 5) 단계의 상등액을 알코올 용액에 침전시키는 단계; 7) 상기 6) 단계의 침전물을 원심분리시켜 상등액을 제거하는 제3 정제 단계; 및 8) 상기 7) 단계의 상등액이 제거되고 남은 침전물을 건조시켜 후코이단(Fucoidan)을 획득하는 단계를 포함한다.A method of extracting fucoidan, which is capable of controlling blood sugar levels, from seaweed according to an embodiment of the present invention includes 1) a pretreatment step of drying and desalting seaweed; 2) a mixing step of mixing the seaweed pretreated in step 1) with an aqueous calcium salt solution; 3) a first purification step of centrifuging the stirred mixture of step 2) and filtering it under reduced pressure; 4) precipitating the filtered mixture of step 3) in an alcohol solution; 5) a second purification step of centrifuging the precipitate from step 4) to obtain a supernatant; 6) Precipitating the supernatant of step 5) in an alcohol solution; 7) a third purification step of centrifuging the precipitate from step 6) to remove the supernatant; and 8) obtaining fucoidan by removing the supernatant of step 7) and drying the remaining precipitate.
상기 후코이단(Fucoidan)은 황산기가 부착된 다당류(평균 분자량 20,000)로써 항암, 항고혈압, 항염증 등에 효능이 있고, 해조류에 존재하는 것이 특징이다.Fucoidan is a polysaccharide (average molecular weight 20,000) with a sulfate group attached, and is effective in anticancer, antihypertensive, anti-inflammatory, etc., and is characterized by being present in seaweed.
본 발명의 1) 단계는 해조류를 건조 및 탈염시키는 전처리 단계로, 해조류에 포함된 후코이단(Fucoidan)을 고순도로 추출하기 위해 해조류로부터 수분 및 염류를 제거하는 단계이다.Step 1) of the present invention is a pretreatment step of drying and desalting seaweed, and is a step of removing moisture and salts from seaweed to extract high purity Fucoidan contained in seaweed.
상기 해조류의 수분은 자연 건조를 통해 제거되며, 상기 자연 건조는 해조류를 태양열과 자연풍을 이용하여 건조시키는 것으로, 구름양이 적은 맑은 날씨의 경우 1 내지 2일 정도 건조시키는 것이 바람직하다.The moisture of the seaweed is removed through natural drying, which involves drying the seaweed using solar heat and natural wind. In clear weather with little cloud cover, it is preferable to dry the seaweed for about 1 to 2 days.
상기 해조류의 염류는 자연 건조된 해조류를 연속적으로 흐르는 담수 내에서 염류를 용출시킨 후 탈염을 통해 제거되며, 상기 탈염은 담수를 사용하여 건조된 해조류가 충분히 잠길 수 있도록 넣고, 담수의 연속적인 교환을 실시하여 해조류 표면의 이물질 및 해조류 내의 염류를 용출시킨 후 수분을 충분히 제거하기 위함이다.The salts of the seaweed are removed through desalting after the salts are eluted from naturally dried seaweed in continuously flowing fresh water. The desalting process is performed by using fresh water to sufficiently submerge the dried seaweed and continuously exchanging fresh water. This is done to sufficiently remove moisture after eluting foreign substances on the surface of the seaweed and salts within the seaweed.
상기 1) 단계에서 전처리된 해조류는 후코이단 성분뿐만아니라, 알긴산(alginic acid), 라미나린(laminarin) 등의 다당류, 비소 등의 중금속 성분을 포함할 수 있다.The seaweed pretreated in step 1) above may contain not only the fucoidan component, but also polysaccharides such as alginic acid and laminarin, and heavy metal components such as arsenic.
본 발명의 2) 단계는 상기 1) 단계의 전처리된 해조류를 칼슘염 수용액과 혼합하는 혼합단계로, 상기 전처리된 해조류에 포함된 알긴산(alginic acid)을 제거하기 위해 칼슘염 수용액과 혼합하는 단계이다.Step 2) of the present invention is a mixing step of mixing the seaweed pretreated in step 1) with an aqueous calcium salt solution, and is a step of mixing with an aqueous calcium salt solution to remove alginic acid contained in the pretreated seaweed. .
상기 2) 단계의 칼슘액 수용액은 전처리된 해조류 내의 알긴산을 알긴산염으로 응집시킬 수 있으며, 알긴산염 응집 작용은 교반을 통해 이루어지는 것이다. The aqueous calcium solution in step 2) can coagulate the alginate in the pretreated seaweed into alginate, and the alginate coagulation action is achieved through stirring.
본 발명의 3) 단계는 상기 2) 단계의 교반된 혼합물을 원심분리시켜 감압 여과하는 제1 정제 단계로, 상기 2) 단계로 인해 응집된 알긴산염을 원심분리를 통해 분리하고 감압 여과를 통해 정제되는 것이다.Step 3) of the present invention is a first purification step in which the stirred mixture of step 2) is centrifuged and filtered under reduced pressure, and the alginate aggregated due to step 2) is separated through centrifugation and purified through reduced pressure filtration. It will happen.
상기 감압 여과를 통해 여과된 혼합물은 알긴산(alginic acid)이 제거되는 것이다.Alginic acid is removed from the mixture filtered through reduced pressure filtration.
상기 원심분리는 6000 rpm 내지 7000 rpm 속도로, 10 내지 30 분에서 이루어지는 것이 바람직하며, 감압 여과는 20 내지 25 ㎛의 NO. 4 여과지를 사용할 수 있다.The centrifugation is preferably performed at a speed of 6000 rpm to 7000 rpm for 10 to 30 minutes, and the reduced pressure filtration is performed using 20 to 25 ㎛ NO. 4 Filter paper can be used.
또한, 상기 알긴산을 제거하는 방법은 원심분리 및 감압 여과를 통해 알긴산염을 수거하는 것이 바람직하나, 침전된 알긴산염의 수거방법은 특별히 제한적인 것은 아니다. In addition, the method for removing alginate is preferably to collect alginate through centrifugation and reduced-pressure filtration, but the method for collecting precipitated alginate is not particularly limited.
본 발명의 4) 단계는 상기 3) 단계의 여과된 혼합물을 알코올 용액에 침전시키는 단계로, 상기 3) 단계를 통해 알긴산(alginic acid)이 여과된 혼합물에 존재하는 라미나린(laminarin)을 침전시키는 단계이다.Step 4) of the present invention is a step of precipitating the filtered mixture of step 3) in an alcohol solution, and through step 3), alginic acid precipitates laminarin present in the filtered mixture. It's a step.
상기 라미나린(laminarin)은 갈조류의 세포벽 속에 들어 있는 탄수화물로, 고등 식물의 녹말에 해당하는 저장성 다당류이며, 주로 다시마류에서 발견된다.The laminarin is a carbohydrate contained in the cell wall of brown algae, a storage polysaccharide equivalent to the starch of higher plants, and is mainly found in kelp.
상기 4) 단계의 알코올 용액은 순수한 에탄올 용액이 아닌, 30% 내지 50% 희석 범위에서 희석된 에탄올 용액으로, 바람직하게는 40%로 희석된 에탄올 용액을 사용하는 것이다.The alcohol solution in step 4) is not a pure ethanol solution, but an ethanol solution diluted in the range of 30% to 50% dilution, and preferably an ethanol solution diluted to 40%.
상기 4) 단계는 3 내지 6시간 동안 침전시키는 단계로, 3 내지 6℃에서 이루어지는 것이 바람직하다.Step 4) is a step of precipitation for 3 to 6 hours, and is preferably performed at 3 to 6°C.
본 발명의 5) 단계는 상기 4) 단계의 침전물을 원심분리시켜 상등액을 수득하는 제2 정제단계로, 상기 4) 단계로 인해 침전된 라미나린(laminarin)을 원심분리를 통해 분리하고, 상등액 수거를 통해 정제되는 것이다.Step 5) of the present invention is a second purification step in which the precipitate of step 4) is centrifuged to obtain a supernatant. The laminarin precipitated in step 4) is separated by centrifugation, and the supernatant is collected. It is refined through.
상기 상등액은 라미나린(laminarin)이 제거된 고순도의 후코이단(Fucoidan)을 포함하는 것이다. The supernatant contains high purity fucoidan from which laminarin has been removed.
상기 원심분리는 6000 rpm 내지 7000 rpm 속도로, 10 내지 30 분에서 이루어지는 것이 바람직하다.The centrifugation is preferably performed at a speed of 6000 rpm to 7000 rpm for 10 to 30 minutes.
상기 본 발명의 제1 내지 제3 정제 단계는 해조류로부터 다른 이물질을 제거하는 단계로서, 후코이단(Fucoidan)을 제외한 알긴산(alginic acid), 라미나린(laminarin) 등의 다당류, 비소 등의 중금속 성분을 제거하여, 후코이단의 순도를 더욱 높일 수 있는 것이다.The first to third purification steps of the present invention are steps to remove other foreign substances from seaweed, removing polysaccharides such as alginic acid and laminarin, and heavy metal components such as arsenic, excluding fucoidan. Thus, the purity of fucoidan can be further increased.
본 발명의 6) 단계는 상기 5) 단계의 상등액을 알코올 용액에 침전시키는 단계로, 상기 5) 단계의 상등액에 포함되어 있는 고순도의 후코이단(Fucoidan)을 침전시키는 단계이다.Step 6) of the present invention is a step of precipitating the supernatant of step 5) in an alcohol solution, and is a step of precipitating high purity fucoidan contained in the supernatant of step 5).
상기 6) 단계는 3 내지 6시간 동안 침전시키는 단계로, 3 내지 6℃에서 이루어지는 것이 바람직하다.Step 6) is a step of precipitation for 3 to 6 hours, and is preferably performed at 3 to 6°C.
상기 6) 단계의 알코올 용액은 순수한 에탄올 용액이 아닌, 60% 내지 80% 희석 범위에서 희석된 에탄올 용액으로, 바람직하게는 70%로 희석된 에탄올 용액을 사용하는 것이다.The alcohol solution in step 6) is not a pure ethanol solution, but an ethanol solution diluted in the 60% to 80% dilution range, and preferably an ethanol solution diluted to 70%.
본 발명의 7) 단계는 상기 6) 단계의 침전물을 원심분리시켜 상등액을 제거하는 제3 정제단계로, 상기 6) 단계로 인해 침전된 후코이단(Fucoidan)을 원심분리를 통해 분리하고, 상등액을 제거하여 고순도의 후코이단을 얻기 위함이다. Step 7) of the present invention is a third purification step in which the precipitate of step 6) is centrifuged to remove the supernatant. Fucoidan precipitated in step 6) is separated by centrifugation and the supernatant is removed. This is to obtain high purity fucoidan.
상기 원심분리는 6000 rpm 내지 7000 rpm 속도로, 10 내지 30 분에서 이루어지는 것이 바람직하다.The centrifugation is preferably performed at a speed of 6000 rpm to 7000 rpm for 10 to 30 minutes.
본 발명의 8) 단계는 상기 7) 단계의 상등액이 제거되고 남은 침전물을 건조시켜 후코이단(Fucoidan)을 획득하는 단계로, 알긴산(alginic acid), 라미나린(laminarin) 등의 다당류, 비소 등의 중금속 성분이 제거되고 남은 침전물로부터 고순도의 후코이단(Fucoidan)을 획득하는 단계이다.Step 8) of the present invention is a step of obtaining fucoidan by removing the supernatant of step 7) and drying the remaining precipitate, which removes polysaccharides such as alginic acid and laminarin, and heavy metals such as arsenic. This is the step of obtaining high purity Fucoidan from the sediment remaining after the components are removed.
상기 칼슘염 수용액은 염화칼슘(CaCl2) 수용액, 탄산칼슘(CaCO3) 수용액, 수산화칼슘(Ca(OH)2) 및 이들의 혼합으로 이루어진 군으로부터 선택되는 것이다.The calcium salt aqueous solution is selected from the group consisting of calcium chloride (CaCl 2 ) aqueous solution, calcium carbonate (CaCO 3 ) aqueous solution, calcium hydroxide (Ca(OH) 2 ), and mixtures thereof.
상기 칼슘염 수용액은 첨가하는 않는 경우, 알긴산(alginic acid)이 충분히 제거되지 않아, 후코이단(Fucoidan) 추출 시 알긴산이 잔류되는 문제점이 있다. If the calcium salt aqueous solution is not added, alginic acid is not sufficiently removed, and there is a problem in that alginic acid remains during Fucoidan extraction.
바람직하게는 상기 칼슘염 수용액은 염화칼슘(CaCl2) 수용액을 사용하는 것이다.Preferably, the calcium salt aqueous solution is an aqueous calcium chloride (CaCl 2 ) solution.
더 바람직하게 상기 칼슘염 수용액은 중금속 흡착 조성물을 더 포함할 수 있다.More preferably, the calcium salt aqueous solution may further include a heavy metal adsorption composition.
상기 중금속 흡착 조성물은 타임(Thymus vulgaris) 추출물, 캐롭(Ceratonia siliqua (L.) Taub.) 추출물 및 도랭이 사초(Carex nubigena var. albata) 추출물을 포함하는 것으로, 항균 작용을 나타낼 수 있어, 해조류에 포함되어 있는 유해균 및 비소 등의 중금속 성분을 제거할 수 있다.The heavy metal adsorption composition includes thyme (Thymus vulgaris) extract, carob (Ceratonia siliqua (L.) Taub.) extract, and carob sedge (Carex nubigena var. albata) extract, and can exhibit antibacterial activity, making it effective against seaweed. It can remove harmful bacteria and heavy metals such as arsenic.
상기 타임 및 캐롭 등의 허브식물은 꽃과 종자, 줄기, 잎, 뿌리 등이 인간에게 유용하게 사용되는 초본식물로 예로부터 진통, 진정 등의 치료나 방부 및 살충을 위한 약초로서 중요한 역할을 해왔으며 오늘날에는 인체에 대한 화학물질의 독성, 환경 오염에 대한 우려 및 그 뛰어난 효능으로 인하여 더더욱 많은 주목을 받고 있는 천연소재이다.Herbal plants such as thyme and carob are herbaceous plants whose flowers, seeds, stems, leaves, and roots are useful to humans, and have played an important role since ancient times as medicinal herbs for pain relief, sedation, etc., as well as for preservatives and insecticides. Today, it is a natural material that is receiving more and more attention due to the toxicity of chemicals to the human body, concerns about environmental pollution, and its excellent efficacy.
상기 타임(Thymus vulgaris)은 꿀풀과에 속하는 방향성 식물로 회색빛을 띤 녹색의 작은 잎을 갖고 있으며, 주 품종으로 두가지를 꼽을 수 있는데 하나는 세르폴레(serpolet)라는 이름으로도 불리는 남프랑스 품종(meridionale, 야생 타임)이고 다른 하나는 겨울 타임(thym dhiver), 독일 타임(thym allemand), 또는 파리굴(farigoule)이라고도 불리는 품종(Thymus vulgaris)으로 더 키가 크고 잎이 더 넓으며 쌉싸름한 맛이 더 강하다. 레몬 타임(thym citron, T. citriodorus) 또한 다양한 요리에 산뜻한 향을 내는 용도로 많이 쓰인다. 타임은 향이 매우 좋고 살균 효능을 가진 에센셜 오일 티몰(thymol)을 함유하고 있다. 요리의 기본 향신허브 중 하나인 타임은 생으로 혹인 말려서 단독으로 사용하거나 부케가르니를 만드는 데 넣는다.The thyme (Thymus vulgaris) is an aromatic plant belonging to the Lamiaceae family and has grayish green small leaves. There are two main varieties, one of which is the southern French variety also called serpolet ( meridionale (wild thyme) and the other (Thymus vulgaris), also called winter thyme (thym dhiver), German thyme (thym allemand), or farigoule, is taller, has wider leaves, and a bitter taste. stronger. Lemon thyme (thym citron, T. citriodorus) is also widely used to give a refreshing flavor to various dishes. Thyme has a very pleasant scent and contains the essential oil thymol, which has antiseptic properties. Thyme, one of the basic cooking herbs, can be used fresh or dried and used alone or used to make a bouquet garni.
상기 캐롭{Ceratonia siliqua (L.) Taub.}은 높이가 10m 정도 자라는 상록 활엽 관목(灌木)으로, 가뭄에 잘 견딘다. 잎에 수지를 함유하고 있다. 가을에 작고 우중충한 녹갈색의 꽃이 피며, 녹색의 긴 꼬투리가 달린다. 이 꼬투리는 익으면 초콜릿색으로 변하고, 속에는 작고 광택이 나는 딱딱한 콩이 들어 있다. 피부를 부드럽게 하는 캐롭 검(Carob gum)은 피부 팩으로 인기가 있으며, 설사 치료에 쓰이기도 한다.The carob {Ceratonia siliqua (L.) Taub.} is an evergreen broad-leaved shrub that grows to a height of about 10 m and is drought tolerant. The leaves contain resin. Small, dark greenish-brown flowers bloom in the fall, and long green pods hang from them. These pods turn chocolate-colored when ripe, and contain small, shiny, hard beans inside. Carob gum, which softens the skin, is popular as a skin pack and is also used to treat diarrhea.
상기 도랭이 사초(Carex nubigena var. albata)는 외떡잎식물 벼목 사초과의 여러해살이풀로, 산과 들에서 자란다. 뿌리줄기는 짧고, 줄기는 가늘고 길며 세모지고 뭉쳐나며 곧게선다. 높이는 30cm 정도이다. 잎은 뭉쳐나고 줄 모양이며 끝이 뾰족하다. 잎은줄기보다 짧거나 길며 나비 3mm 정도이다. 꽃은 4∼6월에 핀다. 꽃이삭은 줄기 끝에 곧게 서고 원기둥 모양이며 길이 25∼40mm 정도이다. 밑동에 짧은 줄 모양의 포가 있고 작은이삭은 양성으로 길이가 5mm 정도이다. 암꽃영은 달걀 모양으로 끝이 뾰족하고 다갈색이다. 과낭은 달걀 모양바소꼴로 길이 4∼5mm이고 영보다 길며, 암술대는 2개이다. 전라북도, 경기도, 평안남도, 평안북도, 함경남도, 함경북도 등지에 분포한다. The above-mentioned sedge (Carex nubigena var. albata) is a perennial herb of the monocot family Cyperaceae and grows in mountains and fields. The rhizome is short, and the stem is thin, long, triangular, clustered, and stands upright. The height is about 30cm. The leaves are clustered, line-shaped, and have sharp ends. The leaves are shorter or longer than the stem and are about 3mm wide. Flowers bloom from April to June. The flower spike stands straight at the end of the stem, has a cylindrical shape, and is about 25-40 mm long. There are short, rope-shaped bracts at the base, and the spikelets are bisexual and about 5 mm long. The female flower inflorescence is egg-shaped, has a pointed tip, and is dark brown. The fruit sac is egg-shaped, 4-5 mm long, longer than the inflorescence, and has two styles. It is distributed in Jeollabuk-do, Gyeonggi-do, South Pyongan Province, North Pyongan Province, South Hamgyong Province, and North Hamgyong Province.
상기 추출물은 물, C1 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택된 추출 용매를 이용하여 추출되는 것이다.The extract is extracted using an extraction solvent selected from the group consisting of water, C 1 to C 6 lower alcohols, and mixtures thereof.
구체적으로, 추출물을 제조하기 위해서는 천연물을 세척하는 단계; 세척 후 건조시키는 단계; 건조 후 천연물을 분쇄하는 단계; 유기 용매를 사용하여 상기 분쇄물을 침출시키는 단계; 시료를 침출 후 건조시키는 단계; 물을 이용하여 침출시키는 단계; 및 침출하는 단계를 포함하여, 잣나무 송이 추출물을 획득할 수 있다.Specifically, to prepare the extract, there are steps of washing the natural product; Drying after washing; Grinding the natural product after drying; leaching the pulverized material using an organic solvent; Leaching and drying the sample; Leaching using water; And including the step of leaching, a pine cluster extract can be obtained.
상기 유기 용매를 사용하여 추출한 천연 추출물은 유기 용매를 사용하여 분획을 실시하는 단계를 더 포함할 수 있다.The natural extract extracted using the organic solvent may further include the step of fractionation using the organic solvent.
상기 추출물을 제조하는 방법은 초음파 추출법, 침출법 및 환류 추출법 등 당업계의 통상적인 추출 방법일 수 있다. 구체적으로 세척 및 건조로 이물질이 제거된 천연물을 물, 탄소수 1 내지 6의 알코올 또는 이들의 혼합 용매로 추출한 추출물일 수 있으며, 상기 용매들을 순차적으로 시료에 적용하여 추출한 추출물일 수 있다.The method of preparing the extract may be a conventional extraction method in the art, such as ultrasonic extraction, leaching, and reflux extraction. Specifically, it may be an extract obtained by extracting a natural product from which foreign substances have been removed by washing and drying with water, alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof, and may be an extract obtained by sequentially applying the solvents to the sample.
상기 환류 추출법은 물, 탄소수 1 내지 6의 알코올 100 mL기준으로, 천연물의 분쇄물 10 내지 30g, 환류 시간 1 내지 3시간 및 탄소수 1 내지 6의 알코올 또는 물에 의한 것이다.The reflux extraction method is based on 100 mL of water and alcohol having 1 to 6 carbon atoms, 10 to 30 g of pulverized natural product, reflux time of 1 to 3 hours, and alcohol or water having 1 to 6 carbon atoms.
보다 구체적으로, 탄소수 1 내지 6의 알코올 100 mL 또는 물 100mL 기준으로, 천연물의 분쇄물 10 내지 20g, 환류 시간 1 내지 2시간 및 탄소수 1 내지 4의 알코올 또는 물에 의한 것이다.More specifically, based on 100 mL of alcohol with 1 to 6 carbon atoms or 100 mL of water, 10 to 20 g of pulverized natural product, reflux time of 1 to 2 hours, and alcohol or water with 1 to 4 carbon atoms.
상기 침출법은 15 내지 30℃, 24 내지 72시간 동안 진행하며, 추출 용매로 물 또는 탄소수 1 내지 6의 알코올을 이용한다. 보다 구체적으로는 20 내지 25℃, 30 내지 54시간 동안 진행하며, 추출 용매는 물 또는 탄소수 1 내지 6의 알코올에 의한 것이다.The leaching method is carried out at 15 to 30°C for 24 to 72 hours, and water or an alcohol with 1 to 6 carbon atoms is used as an extraction solvent. More specifically, the extraction is performed at 20 to 25°C for 30 to 54 hours, and the extraction solvent is water or an alcohol having 1 to 6 carbon atoms.
상기 초음파 추출법은 30 내지 50℃, 0.5 내지 2.5시간 동안 반응을 진행하며, 추출용매는 물 또는 탄소수 1 내지 6의 알코올에 의한 것이다. 구체적으로는 40 내지 50℃, 1 내지 2.5시간 동안 추출하며, 추출용매로 물 또는 탄소수 1 내지 6의 알코올에 의한 것이다.The ultrasonic extraction method proceeds at 30 to 50°C for 0.5 to 2.5 hours, and the extraction solvent is water or an alcohol with 1 to 6 carbon atoms. Specifically, extraction is performed at 40 to 50°C for 1 to 2.5 hours, and the extraction solvent is water or an alcohol with 1 to 6 carbon atoms.
상기 추출 용매는 시료의 중량 기준으로 2 내지 50배를 사용할 수 있으며, 보다 구체적으로는 2 내지 20배이다. 추출을 위해 시료는 추출 용매에서 침출을 위해 1 내지 72시간 동안 방치될 수 있으며, 보다 구체적으로 24 내지 48시간 동안 방치될 수 있다.The extraction solvent can be used in an amount of 2 to 50 times, more specifically, 2 to 20 times the weight of the sample. For extraction, the sample may be left for 1 to 72 hours, more specifically, 24 to 48 hours for leaching in the extraction solvent.
추출 후, 추출물은 새로운 분획 용매를 순차적으로 적용하여 분획할 수 있다. 분획시 사용하는 분획 용매는 상기 용매는 물, 헥산, 부탄올, 에틸아세트산, 에틸 아세테이트, 메틸렌클로라이드 및 이들의 혼합물로 이루어진 군으로부터 선택된 어느 하나 이상이며, 바람직하게는 에틸아세테이트 또는 메틸렌클로라이드이다.After extraction, the extract can be fractionated by sequentially applying a new fractionation solvent. The fractionating solvent used during fractionation is at least one selected from the group consisting of water, hexane, butanol, ethyl acetic acid, ethyl acetate, methylene chloride, and mixtures thereof, and is preferably ethyl acetate or methylene chloride.
추출물 또는 분획물을 얻은 후에는 농축 또는 동결건조 등의 방법을 추가적으로 사용할 수 있다.After obtaining the extract or fraction, additional methods such as concentration or freeze-drying can be used.
바람직하게 상기 중금속 흡착 조성물은 타임 추출물 100 중량부에 대하여, 캐롭 추출물 100 중량부 및 도랭이 사초 추출물 40 내지 60 중량부를 포함하는 것이다.Preferably, the heavy metal adsorbing composition contains 100 parts by weight of carob extract and 40 to 60 parts by weight of cypress sedge extract, based on 100 parts by weight of thyme extract.
상기 범위에 의하는 경우, 우수한 항균 작용으로 중금속 흡착 효과를 높이는 동시에, 후코이단을 제외한 각종 유해균을 제거할 수 있어 고순도의 후코이단 추출이 가능하다. In the case within the above range, the heavy metal adsorption effect can be increased through excellent antibacterial action, and various harmful bacteria except fucoidan can be removed, making high purity fucoidan extraction possible.
바람직하게 상기 중금속 흡착 조성물은 본 발명의 2) 단계의 칼슘염 수용액에 포함되는 것으로, 상기 2) 단계에서 칼슘염 수용액 100 중량부에 대하여, 중금속 흡착 조성물 10 내지 30 중량부로 혼합되어 교반되는 것이다.Preferably, the heavy metal adsorption composition is included in the calcium salt aqueous solution of step 2) of the present invention, and in step 2), 10 to 30 parts by weight of the heavy metal adsorption composition is mixed and stirred with respect to 100 parts by weight of the calcium salt aqueous solution.
상기 타임 추출물, 캐롭 추출물 및 도랭이사초 추출물을 포함하는 중금속 흡착 조성물을 더 혼합하여 교반하는 경우, 칼슘염 수용액에 의해 완전히 제거되지 않은 잔류 알긴산 및 비소 등의 중금속을 흡착 제거할 수 있으며, 상기 범위에 의하는 경우, 우수한 알긴산 제거 효과와 알긴산을 제외한 다른 당류 등의 농도를 낮춰 후코이단의 순도를 더욱 높일 수 있다. When the heavy metal adsorption composition containing the thyme extract, carob extract, and Eucalyptus extract is further mixed and stirred, heavy metals such as residual alginic acid and arsenic that have not been completely removed by the aqueous calcium salt solution can be adsorbed and removed, and within the above range. In this case, the purity of fucoidan can be further increased by providing an excellent alginic acid removal effect and lowering the concentration of other sugars other than alginic acid.
또한, 상기 범위를 초과하여 첨가하는 경우에 잔류 알긴산 및 비소 등의 중금속을 흡착 제거하는데 필요 이상으로 투입되어 고순도의 후코이단을 추출하는데 문제점이 있다.In addition, when added in excess of the above range, more than necessary is added to adsorb and remove heavy metals such as residual alginic acid and arsenic, causing problems in extracting high purity fucoidan.
상기 해조류는 미역귀, 톳, 모자반, 다시마, 꼬시래기, 뜸부기 및 이들의 혼합으로 이루어진 군으로부터 선택되는 것이다.The seaweed is selected from the group consisting of seaweed, hijiki, kelp, seaweed, seaweed, seaweed, and mixtures thereof.
상기 해조류는 갈조류의 일종으로, 미역귀, 톳, 모자반, 다시마, 꼬시래기, 듬부기 등을 포함하며, 이에 제한되지 않고, 후코이단 성분을 포함하는 것이라면 모두 포함될 수 있다. 바람직하게는 톳 또는 뜸부기를 사용하는 것이 좋다.The seaweed is a type of brown algae and includes, but is not limited to, seaweed, hijiki, seaweed, kelp, seaweed, seaweed, etc., and may include any species that contains a fucoidan component. Preferably, it is better to use hijiki or moxa.
상기 미역귀는 미역의 씨앗을 방출하는 포자엽(뿌리)로서, 과거 식감이 떨어지고 판로가 없어 유통되지 않았으나, 미역귀는 100g당 후코이단 함량이 12.8g으로 미역잎의 7배에 달한다.The seaweed ear is a sporophyll (root) that releases the seeds of seaweed. In the past, it was not distributed due to poor texture and lack of a market, but the fucoidan content of seaweed ear is 12.8g per 100g, which is 7 times that of seaweed leaf.
상기 톳(Sargassum fusiforme)은 바닷말의 일종으로, 청 정해 완도및 서남해(남해안일대)에서 자연산과 양식으로 생산되는 갈조식물이다. 톳은 갈색말 무리에 속한다. 칼슘, 요오드, 철, 마그네슘 등이 매우 풍부하다. The hijiki (Sargassum fusiforme) is a type of seaweed and is a brown algae plant produced naturally and farmed in the clean waters of Wando and the southwest sea (the southern coast area). Tot belongs to the brown horse group. It is very rich in calcium, iodine, iron, and magnesium.
상기 모자반(Sargassum)은 모자반속(Sargassum) 조류의 총칭으로, 특정 종 Sargassum fulvellum 또는 대형 갈조류를 통칭하는 말로도 쓰인다. 몸은 외견상 뿌리·줄기·잎의 구분이 뚜렷하고, 뿌리는 가반상(假盤狀)이며 1개의 중심 가지를 내어 1-3m 이상 크게 자란다. 줄기는 삼릉주 또는 삼각형이고 비틀린다. 잎은 줄기에서 기부 쪽으로 향하여 나며 휘어지고, 주걱 모양 또는 타원형을 하고 잎 중앙부까지 중륵이 생긴다. 상부의 잎은 피침형이고 가장자리에 톱니 모양의 돌기가 나며, 온몸에는 줄기부터 기포가 생긴다. 짙은 황갈색을 하고 한국의 전 해안에서 볼 수 있다. 식용으로 이용되는 모자반류의 대표적인 종류로, 흔히 시장에서 팔고 있다. 모자반속은 난해성 식물로서 여러해살이며 한국의 연안에서 해중림을 이루는 대표적인 종류이다. Sargassum is a general term for algae of the genus Sargassum, and is also used as a general term for a specific species of Sargassum fulvellum or large brown algae. The body has a clear division into roots, stems, and leaves. The roots are ridged and produce one central branch that grows to a height of 1-3 m or more. The stem is triangular or triangular and twisted. The leaves grow from the stem toward the base, are curved, have a spatula shape or an oval shape, and have a midrib extending to the center of the leaf. The upper leaves are lanceolate and have serrated protrusions on the edges, and air bubbles form all over the body starting from the stem. It has a dark tan color and can be found along the entire coast of Korea. It is a representative type of mogaban used for food, and is commonly sold in the market. Caprifolia is a perennial plant that is difficult to digest and is a representative species that forms marine forests along the coast of Korea.
모자반은 지충이, 괭생이모자반, 알쏭이모자반, 꽈배기모자반, 큰잎모자반, 짝잎모자반, 쌍발이모자만 등 약 20종이 채집되며, 일본이나 동남아시아 일대에는 50여 종이 생육하고 있다. 모자반속이 무성한 곳은 각종 연안동물들이 먹이를 얻거나 산란하기에 적합하여, 환경보존과 어업자원 확보를 위해서도 매우 중요한 구실을 한다. 한국에서도 모자반속의 많은 종류가 식용되기도 하며, 알긴산 등 해조 공업의 원료로 이용되거나 비료로도 쓰인다.Approximately 20 species of caps are collected, including the earthworm, the hoe-shaped cap, the egg-shaped cap, the twirl-shaped cap, the large-leaf cap, the double-leaf cap, and the double-leaf cap, and about 50 species are growing in Japan and Southeast Asia. Places with lush moss are suitable for various coastal animals to obtain food or lay eggs, and play a very important role in preserving the environment and securing fishing resources. In Korea, many species of the genus Mojapan are edible, and are used as raw materials for the seaweed industry, such as alginic acid, or as fertilizer.
상기 다시마(Saccharina japonica)는 갈조류에 속하는 해양식물로써, 한국, 중국 및 일본에서는 식품 소재로 이용되고 있다. 다시마는 자연환경에서는 물론이고 바다에서 양식을 통하여 육성될 수 있는데, 탄수화물, 다당류, 카로틴류, 엽록소를 포함한 여러 색소 외에 알긴산, 요오드, 비타민 B2, 후코이단 등이 들어있다.The kelp (Saccharina japonica) is a marine plant belonging to brown algae and is used as a food material in Korea, China, and Japan. Kelp can be cultivated in natural environments as well as in the sea. It contains various pigments including carbohydrates, polysaccharides, carotenes, and chlorophyll, as well as alginic acid, iodine, vitamin B2, and fucoidan.
상기 꼬시래기(Gracilaria verrucose)는 홍조식물 꼬시래기과의 해조로, 몸은 깃꼴로 나누어지고 빛깔은 검은 자주빛 또는 어두운 갈색이다. 우무를 만들 때 우뭇가사리와 섞어 쓴다. 장흥·완도·해남·진도에서는 꼬시락이라 하며, 부산근처에서는 망둑어를 꼬시래기라고 부르기도 한다. Gracilaria verrucose is a seaweed of the red algae family Gracilaria verrucose. Its body is divided into feathers and its color is black purple or dark brown. When making agar agar, it is mixed with agar agar. In Jangheung, Wando, Haenam, and Jindo, it is called kosirak, and near Busan, goby fish is also called kosiraegi.
상기 뜸부기(Pelvetia siliquosa)는 갈조식물 뜸부기과의 바닷말로, 남해안과 서해안에서 자란다. 한국산 뜸부기는 일본에서 나는 ‘Pelvetia wrightii’와 같은 종으로 알려졌으나 중국의 해조학자가 서해 연안에서 나는 종류가 일본산과는 달리 몸이 작고 직립하는 특징을 지닌다 하여 ‘P. siliquosa’라는 새로운 이름을 붙였다(1953년). 뜸부기는 흔히 식용되며 알긴산 원료로도 이용된다.The Pelvetia siliquosa is a seaweed from the brown algae family, growing on the southern and western coasts. Korean moxa is known to be the same species as ‘Pelvetia wrightii’ from Japan, but a Chinese seaweed scientist found that the species from the West Sea, unlike the Japanese one, has a small and upright body, so ‘P. A new name was given, ‘siliquosa’ (1953). Moxa is commonly eaten and is also used as a raw material for alginic acid.
상기 후코이단(Fucoidan)은 600 내지 900KDa의 분자량을 나타내는 것이다.The fucoidan has a molecular weight of 600 to 900 KDa.
해조류에 포함되어 있는 후코이단의 분자량은 평균 MW 20KDa이며 후코스(Fucose)라는 기본당과 황산기가 결합되어 있다. 황산화 후코이단에서 생기는 F-후코이단과 20% 정도의 글루쿠론산를 포함한 U-후코이단 두 종류가 있다.The average molecular weight of fucoidan contained in seaweed is MW 20KDa, and it is a basic sugar called fucose combined with a sulfate group. There are two types: F-fucoidan, which comes from sulfated fucoidan, and U-fucoidan, which contains about 20% glucuronic acid.
특히 후코이단은 높은 비율로 황산기를 포함하는 다당류(sulfated polysaccharide) 로서 다시마 등의 갈조류 및 해삼, 성게와 같은 몇몇 해양 무척추동물로부터 유래되는 일반적으로 300 kDa을 초과하는 분자량을 갖는 거대분자이다. 이러한 후코이단은 항염, 항암, 면역조절, 항응고, 항혈전, 항산화 등의 다양한 생물학적 활성을 가지는 것으로 보고되어 있으나, 우리 몸은 자체적으로 후코이단을 분해하여 저분자화하지 못하므로 고분자 상태의 후코이단을 그대로 섭취할 경우에는 다량 섭취한다 할지라도 대부분은 체내로 흡수되지 못한 채 배설된다.In particular, fucoidan is a sulfated polysaccharide containing a high proportion of sulfate groups and is a macromolecule with a molecular weight generally exceeding 300 kDa derived from brown algae such as kelp and some marine invertebrates such as sea cucumbers and sea urchins. Fucoidan has been reported to have various biological activities such as anti-inflammatory, anticancer, immunomodulatory, anticoagulant, antithrombotic, and antioxidant. However, since our body cannot break down fucoidan into low molecules on its own, we ingest fucoidan in its high molecular form as is. Even if a large amount is consumed, most of it is excreted without being absorbed into the body.
상기한 바와 같이 다양한 생물학적 활성을 나타내는 후코이단의 수많은 장점에도 불구하고 갈조류 등으로부터 추출한 후코이단의 분자량이 20KDa 일뿐만 아니라 알긴산을 포함한 다당류들을 포함하고 있어 1,000KDa이상의 고분자 물질이기 때문에 섭취하였을 경우 흡수율이 매우 떨어진다는 단점이 있어 후코이단의 흡수를 위해서는 저분자화된 제품을 섭취하는 것이 바람직하므로, 후코이단의 저분자화 제조 방법 개발이 요구되고 있는 상황이다.As mentioned above, despite the numerous advantages of fucoidan, which exhibits various biological activities, the molecular weight of fucoidan extracted from brown algae is not only 20 KDa, but also contains polysaccharides including alginic acid, making it a high molecular weight substance of over 1,000 KDa, so its absorption rate is very low when ingested. has a disadvantage, so it is desirable to consume low-molecular-weight products to absorb fucoidan, so the development of a low-molecular-weight manufacturing method for fucoidan is required.
본 발명의 방법에 따라 추출된 후코이단(Fucoidan)은 600 내지 900KDa의 분자량을 나타내는 것으로, 섭취 시 체내 흡수율을 높일 수 있는 것이다.Fucoidan extracted according to the method of the present invention has a molecular weight of 600 to 900 KDa, which can increase the absorption rate in the body when ingested.
상기 후코이단(Fucoidan)은 전분분해효소 저해능을 통해, 혈당 조절 효과를 나타내는 것으로, 상기 전분분해효소는 알파-글루코시다제(α-glucosidase)를 포함하는 것이다.The fucoidan exhibits a blood sugar control effect through its ability to inhibit starch-degrading enzymes, and the starch-degrading enzyme includes alpha-glucosidase.
상기 알파-글루코시데이스(α-glucosidase)는 탄수화물을 가수분해하여 알파-글루코오스를 생성하는 분해효소로서, 유기체에 필수적인 에너지 공급을 위한 당을 제공한다. The alpha-glucosidase is a decomposition enzyme that hydrolyzes carbohydrates to produce alpha-glucose, and provides sugar for essential energy supply to organisms.
인간에서는 알파-글루코시데이스가 탄수화물 분해의 마지막 단계에서 작용하기 때문에, 알파-글루코시데이스 매개 혈당의 생성은 건강한 상태를 유지하기 위해 체내에 에너지를 공급한다. 알파-글루코시데이스의 농도가 낮을 경우 폼페병(Pompe's disease) 및 리소좀의 알파-글루코시데이스 결핍에 의해 야기되는 글리코겐 저장 장애와 같은 심각한 병리학적 변화가 나타나며, 이와 대조적으로, 상기 효소의 활성이 높은 경우에는 혈당 수치가 증가할 수 있다.In humans, alpha-glucosidase acts in the final step of carbohydrate breakdown, so alpha-glucosidase-mediated production of blood sugar supplies the body with energy to maintain a healthy state. Low concentrations of alpha-glucosidase result in serious pathological changes such as Pompe's disease and impaired glycogen storage caused by alpha-glucosidase deficiency in lysosomes, in contrast, when the activity of the enzyme is reduced. In high cases, blood sugar levels may increase.
따라서, 본 발명에 따라 추출된 후코이단(Fucoidan)은 알파-글루코시다제(α-glucosidase)의 전분분해효소 저해능을 통해, 혈당 조절 효과를 나타낼 수 있는 것이다.Therefore, Fucoidan extracted according to the present invention can exhibit a blood sugar control effect through the starch-degrading enzyme inhibitory ability of α-glucosidase.
본 발명의 다른 일 실시예에 따른 당뇨병 예방 및 개선용 식품 조성물은 상기 방법에 따라 추출된 후코이단(Fucoidan)을 포함하여 제조되는 것이다.A food composition for preventing and improving diabetes according to another embodiment of the present invention is manufactured including fucoidan extracted according to the above method.
상기 “식품”이란, 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서, 식품, 식품첨가제, 기능성식품 및 음료를 모두 포함하는 것을 말한다.The term “food” refers to a natural product or processed product containing one or more nutrients, preferably in a state that can be eaten directly after a certain degree of processing. In the usual sense, it means food. , which includes all food additives, functional foods, and beverages.
상기 식품용 조성물을 첨가할 수 있는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합체, 기능성 식품 등이 있다. 추가로, 특수영양식품(예, 조제유류, 영, 유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 빵류, 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스낵류), 캔디류, 쵸코렛류, 껌류, 아이스크림류, 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실음료, 채소류 음료, 두유류, 발효음료류 등), 천연 조미료(예, 라면스프 등)를 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다.Foods to which the food composition can be added include, for example, various foods, beverages, gum, tea, vitamin complexes, functional foods, etc. Additionally, special nutritional foods (e.g., milk formula, infant and baby food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), breads, health supplements, seasoned foods (e.g., soy sauce) , soybean paste, red pepper paste, mixed paste, etc.), sauces, confectionery (e.g., snacks), candy, chocolate, gum, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi) , pickles, etc.), beverages (e.g., fruit drinks, vegetable drinks, soy milk, fermented drinks, etc.), and natural seasonings (e.g., ramen soup, etc.), but are not limited thereto. The food, beverage or food additive can be manufactured by conventional manufacturing methods.
또한, 상기 “기능성 식품”또는 “건강기능성 식품”이란 식품에 물리적, 생화학적, 생물 공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체내조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미하며, 구체적으로는 건강 기능성 식품일 수 있다. 상기 기능성 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.In addition, the above-mentioned “functional food” or “health functional food” refers to a food group or food composition that has added value to the food by using physical, biochemical, bioengineering methods, etc. to function and express the function of the food for a specific purpose. It refers to food designed and processed to fully express the body's regulatory functions related to defense rhythm control, disease prevention and recovery, etc., and specifically, it may be a health functional food. The functional food may include food auxiliary additives that are foodologically acceptable, and may further include appropriate carriers, excipients, and diluents commonly used in the production of functional foods.
상기 건강보조식품의 종류로는 이에 제한되지는 않으나, 분말, 과립, 정제, 캡슐 또는 음료 형태 일 수 있다.The type of health supplement is not limited thereto, but may be in the form of powder, granule, tablet, capsule, or beverage.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 이하, 본 발명을 실시예에 의해 상세히 설명하기로 한다. 그러나 이들 실시예들은 본 발명을 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.The advantages and features of the present invention and methods for achieving them will become clear with reference to the embodiments described in detail below. Hereinafter, the present invention will be described in detail through examples. However, these examples are for illustrating the present invention in detail, and the scope of the present invention is not limited to these examples.
본 발명의 다른 일 실시예에 따른 당뇨병 예방 및 치료용 약학 조성물은 상기 방법에 따라 추출된 후코이단을 포함하여 제조되는 것이다.A pharmaceutical composition for preventing and treating diabetes according to another embodiment of the present invention is prepared including fucoidan extracted according to the above method.
본 발명에 따라 추출된 후코이단(Fucoidan)은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. Fucoidan extracted according to the present invention is formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. It can be used interchangeably.
또한, 상기 당뇨병 예방 및 치료용 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.In addition, carriers, excipients, and diluents that may be included in the pharmaceutical composition for preventing and treating diabetes include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, Various compounds or mixtures including calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. I can hear it. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 성분에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, or sucrose. ) or prepared by mixing lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogeratin, etc. can be used.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로 든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition of the present invention varies depending on the patient's condition and weight, degree of disease, drug form, administration route and period, but can be appropriately selected by a person skilled in the art. However, for desirable effects, the composition of the present invention is preferably administered at 0.0001 to 100 mg/kg per day, preferably at 0.001 to 100 mg/kg. Administration may be administered once a day, or may be administered several times. The above dosage does not limit the scope of the present invention in any way.
본 발명의 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법에 의하면 해조류에서 추출된 후코이단의 함유량을 높일 수 있는 추출방법을 통해, 추출 조건을 최적화하고, 후코이단의 추출 비용 및 시간을 절감하여 대량 추출이 가능한 동시에, 초기 전분분해효소의 활성을 조절함으로써 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법을 제공할 수 있다.According to the method of extracting fucoidan capable of controlling blood sugar levels from seaweed of the present invention, the extraction conditions are optimized through an extraction method that can increase the content of fucoidan extracted from seaweed, and the extraction cost and time of fucoidan are reduced, enabling mass extraction. At the same time, it is possible to provide a method of extracting fucoidan, which can control blood sugar levels, from seaweed by controlling the activity of the initial starch-degrading enzyme.
도 1은 본 발명의 일 실시예에 따른 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법을 단계별로 나타낸 것이다.
도 2는 본 발명의 일 실시예에 따른 후코이단 처리에 따른 알파-글루코시다아제 효소활성 저해율을 분석하여 나타낸 결과이다.
도 3은 본 발명의 일 실시예에 따른 추출물의 수율 및 추출물 100g 생산에 필요한 소모성 물품 비용을 나타낸 것이다.
도 4는 본 발명의 일 실시예에 따른 추출물의 분자량 분포도를 나타낸 것이다.
도 5는 본 발명의 일 실시예에 따른 추출물의 알파-글루코시다아제 저해능을 나타낸 것이다.Figure 1 shows a step-by-step method of extracting fucoidan, which is capable of controlling blood sugar levels, from seaweed according to an embodiment of the present invention.
Figure 2 shows the results of analyzing the inhibition rate of alpha-glucosidase enzyme activity according to fucoidan treatment according to an embodiment of the present invention.
Figure 3 shows the yield of the extract and the cost of consumable items required to produce 100 g of the extract according to an embodiment of the present invention.
Figure 4 shows the molecular weight distribution of an extract according to an embodiment of the present invention.
Figure 5 shows the alpha-glucosidase inhibitory ability of an extract according to an embodiment of the present invention.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement it. However, the present invention may be implemented in many different forms and is not limited to the embodiments described herein.
[제조예1: 중금속 흡착 조성물의 제조][Preparation Example 1: Preparation of heavy metal adsorption composition]
1. 허브 추출물의 제조1. Preparation of herbal extract
타임을 흐르는 물에 깨끗이 세척한 다음 완전히 자연 건조시켰다. 건조된 타임을 믹서기로 분쇄한 다음 분말로 제조하였다. 분말 시료를 추출 용매인 50%로 희석된 에탄올을 1;10(w;v)의 비율로 가한 다음 완전히 침지 시킨 후, 80℃에서 환류시키면서 3시간씩 3회 반복 추출하였다. 추출액은 Whatman No. 2 여과지로 여과하였다. 여과액은 60℃에서 감압 농축하여 타임 추출물(TH)을 제조하였다.The thyme was thoroughly washed under running water and then completely air-dried. The dried thyme was ground in a blender and then made into powder. The powder sample was completely immersed in 50% diluted ethanol as an extraction solvent at a ratio of 1:10 (w;v), and then extracted three times for 3 hours while refluxing at 80°C. The extract was Whatman No. 2 Filtered with filter paper. The filtrate was concentrated under reduced pressure at 60°C to prepare thyme extract (TH).
상기 타임 추출물(TH)의 제조 방법과 동일한 방법을 이용하여, 캐롭 추출물(KH)를 제조하였다.Carob extract (KH) was prepared using the same method as the method for producing thyme extract (TH).
2. 도랭이 사초 추출물의 제조2. Preparation of Doraengi sedge extract
도랭이 사초를 세척하고, 건조한 뒤 이를 분쇄하였다. 상기 분쇄물을 60%으로 희석된 에탄올에 혼합하고, 이를 2시간 동안 추출하여, 이를 냉각시킨 뒤 와트만 여과지로 여과한 후, 그 여액을 수득하여 도랭이 사초 추출물(CE)을 제조하였다.Dorangi sedge was washed, dried, and then ground. The pulverized product was mixed with ethanol diluted to 60%, extracted for 2 hours, cooled, and filtered with Whatman filter paper, and the filtrate was obtained to prepare a sedge extract (CE).
3. 중금속 흡착 조성물의 제조3. Preparation of heavy metal adsorption composition
상기 타임 추출물(TH), 캐롭 추출물(TK) 및 도랭이 사초 추출물(CE)을 하기 표 1과 같이 혼합하여 본 발명의 중금속 흡착 조성물로 제조하였다.The thyme extract (TH), carob extract (TK), and cypress sedge extract (CE) were mixed as shown in Table 1 below to prepare the heavy metal adsorption composition of the present invention.
(단위: 중량부)(Unit: parts by weight)
[제조예2: 후코이단의 추출][Preparation Example 2: Extraction of fucoidan]
본 발명의 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법에 따른 효과를 확인하기 위하여 하기의 표 2과 같은 방법으로 각 단계를 구성하여 해조류로부터 후코이단(Fucoidan)을 추출하였다.In order to confirm the effect of the method of extracting fucoidan, which can control blood sugar levels, from seaweed according to the present invention, each step was configured as shown in Table 2 below to extract fucoidan from seaweed.
하기 FUCO4 내지 FUCO9는 본 발명의 S2 단계에서 칼슘염 수용액(CaCl2) 100 중량부에 대하여, 제조예 1에서 제조된 중금속 흡착 조성물 BSC1 내지 BSC6을 각각 20 중량부씩 더 첨가하여 해조류로부터 후코이단(Fucoidan)을 추출한 것이다.The following FUCO4 to FUCO9 are fucoidan from seaweed by adding 20 parts by weight of the heavy metal adsorption composition BSC1 to BSC6 prepared in Preparation Example 1 to 100 parts by weight of the calcium salt aqueous solution (CaCl 2 ) in step S2 of the present invention. is extracted.
S1: 톳을 건조 및 탈염시키는 전처리 단계S1: Pretreatment step of drying and desalting hijiki
S2: 상기 전처리된 해조류를 CaCl2과 85℃에서 4시간 동안 혼합하는 혼합단계S2: Mixing step of mixing the pretreated seaweed with CaCl 2 at 85°C for 4 hours
S3: 상기 교반된 혼합물을 6,500 rpm에서 20분 동안 원심분리시켜 NO 4 여과지에서 감압 여과하는 제1 정제 단계S3: A first purification step in which the stirred mixture is centrifuged at 6,500 rpm for 20 minutes and filtered under reduced pressure on NO 4 filter paper.
S4: 상기 여과된 혼합물을 40%로 희석된 에탄올 용액에 4시간 동안 침전시키는 단계S4: Precipitating the filtered mixture in 40% diluted ethanol solution for 4 hours
S5: 상기 침전물을 6,500 rpm에서 20분 동안 원심분리시켜 상등액을 수득하는 제2 정제 단계;S5: a second purification step of centrifuging the precipitate at 6,500 rpm for 20 minutes to obtain a supernatant;
S6: 상기 상등액을 70%로 희석된 에탄올 용액에 4시간 동안 침전시키는 단계S6: Precipitating the supernatant in an ethanol solution diluted to 70% for 4 hours
S7: 상기 침전물을 6,500 rpm에서 20분 동안 원심분리시켜 상등액을 제거하는 제3 정제 단계S7: Third purification step of removing the supernatant by centrifuging the precipitate at 6,500 rpm for 20 minutes
S8: 최종 생성물을 24시간 동안 열풍 건조시켜 후코이단을 획득하는 단계S8: Obtaining fucoidan by drying the final product with hot air for 24 hours
[실험예1: 본 발명에 따라 추출된 후코이단의 함량 분석][Experimental Example 1: Analysis of the content of fucoidan extracted according to the present invention]
상기 제조예 2에서 획득된 후코이단(FUCO1 내지 FUCO9)의 함량을 분석하기 위해 하기와 같은 실험을 진행하였다.The following experiment was conducted to analyze the content of fucoidan (FUCO1 to FUCO9) obtained in Preparation Example 2.
제조예 2에서 획득된 후코이단 FUCO1 내지 FUCO9를 0.3 mg/mL로 희석한 용액 50 μL와 황산(18 M) 200 μL를 96 well 플레이트에 각각 넣고, 잘 교반한 후 80℃에서 30분 동안 가열하였다. 방냉 후 3%(w/v)의 L-cysteine hydrochloride 8 μL를 플레이트에 추가로 넣고 4℃에서 1시간 동안 보관하였다. 50 μL of fucoidan FUCO1 to FUCO9 obtained in Preparation Example 2 diluted to 0.3 mg/mL and 200 μL of sulfuric acid (18 M) were added to each 96 well plate, stirred well, and heated at 80°C for 30 minutes. After cooling, 8 μL of 3% (w/v) L-cysteine hydrochloride was added to the plate and stored at 4°C for 1 hour.
후코이단의 함량 특정은 HPAEC(High Performance Anion Electric Chtomatography)로 진행하였으며, 검출기는 PAD(Pulsed Amperometry Detector)로 분석하였다. The content of fucoidan was determined using HPAEC (High Performance Anion Electric Chtomatography), and the detector was analyzed using PAD (Pulsed Amperometry Detector).
그 결과를 하기 표 3에 나타내었다.The results are shown in Table 3 below.
(단위: %)(unit: %)
상기 표 3에 나타낸 바와 같이, 본 발명의 제1 정제 단계만 포함하여 추출된 후코이단 FUCO1에 비해, 제2 정제 단계를 더 포함하여 추출된 후코이단 FUCO2와 제2 정제 단계 및 제3 정제 단계를 더 포함하는 후코이단 FUCO3에서 우수한 후코이단 함량을 나타내었다.As shown in Table 3, compared to fucoidan FUCO1 extracted including only the first purification step of the present invention, fucoidan FUCO2 extracted further including a second purification step and further comprising a second purification step and a third purification step Fucoidan FUCO3 showed excellent fucoidan content.
특히, 상기 S2 단계에서 본 발명의 중금속 흡착 조성물(BSC1 내지 BSC6)을 포함하여 후코이단을 추출하는 경우, 알긴산(alginic acid), 라미나린(laminarin) 등의 다당류, 비소 등의 중금속 성분이 제거되어 더욱 우수한 후코이단 함량을 나타내었다.In particular, when extracting fucoidan including the heavy metal adsorption composition (BSC1 to BSC6) of the present invention in step S2, polysaccharides such as alginic acid and laminarin, and heavy metal components such as arsenic are removed, further It showed excellent fucoidan content.
[실험예2: 본 발명에 따라 추출된 후코이단의 혈당 조절 효과][Experimental Example 2: Blood sugar control effect of fucoidan extracted according to the present invention]
상기 제조예 2에서 획득된 후코이단(FUCO1 내지 FUCO9)의 혈당 조절 효과를 확인하기 위해, 상기 후코이단 FUCO1 내지 FUCO9 처리에 따른 알파-글루코시다아제의 저해활성을 확인하였다. In order to confirm the blood sugar control effect of the fucoidan (FUCO1 to FUCO9) obtained in Preparation Example 2, the inhibitory activity of alpha-glucosidase according to the fucoidan FUCO1 to FUCO9 treatment was confirmed.
상기 후코이단 FUCO1 내지 FUCO9의 알파-글루코시다아제에 대한 저해활성은 ρ-니트로페닐-알파-D-글루코피라노사이드(ρ-nitrophenyl-α-Dglucopyranoside)를 기질로 하여 측정하였다.The inhibitory activity of the fucoidans FUCO1 to FUCO9 against alpha-glucosidase was measured using ρ-nitrophenyl-alpha-D-glucopyranoside as a substrate.
0.1 M 인산완충용액(pH 6.8) 40 μL에 상기 후코이단(FUCO1 내지 FUCO9) 10 μL 첨가한 후 희석한 효소용액 25 μL를 첨가하였다. ρ-니트로페닐-알파-D-글루코피라노사이드(ρ-nitrophenyl-α-Dglucopyranoside) 25 μL 첨가한 후 37 ℃에서 30분간 반응시키고 0.2 M 탄산나트륨 용액(sodium carbonate solution) 100 μL를 첨가한 후 반응을 종결시켜 유리된 ρ-니트로페놀(ρ-nitrophenol)의 생성량을 405nm에서 측정하였다.10 μL of the fucoidan (FUCO1 to FUCO9) was added to 40 μL of 0.1 M phosphate buffer solution (pH 6.8), and then 25 μL of the diluted enzyme solution was added. After adding 25 μL of ρ-nitrophenyl-α-Dglucopyranoside, react at 37°C for 30 minutes and add 100 μL of 0.2 M sodium carbonate solution. Upon termination, the amount of free ρ-nitrophenol produced was measured at 405 nm.
반응액에 본 발명의 후코이단(FUCO1 내지 FUCO9) 대신 동량의 상기 인산완충액을 넣어 얻은 값과의 차이로부터 효소활성 저해율을 측정하였으며, 상기 후코이단 FUCO1 내지 FUCO9 처리에 따른 알파-글루코시다아제의 효소활성 저해율은 도 2에 나타내었다.The enzyme activity inhibition rate was measured from the difference between the value obtained by adding the same amount of phosphate buffer solution instead of the fucoidan (FUCO1 to FUCO9) of the present invention to the reaction solution, and the enzyme activity inhibition rate of alpha-glucosidase according to the fucoidan FUCO1 to FUCO9 treatment. is shown in Figure 2.
하기 도 2에 나타낸 바와 같이, 본 발명의 후코이단 FUCO1 내지 FUCO9은 농도의존적으로 알파-글루코시다아제효소의 효소활성을 저해함을 알 수 있었으며, 본 발명의 제1 정제 단계만 포함하여 추출된 후코이단 FUCO1에 비해, 제2 정제 단계를 더 포함하여 추출된 후코이단 FUCO2와 제2 정제 단계 및 제3 정제 단계를 더 포함하는 후코이단 FUCO3에서 우수한 알파-글루코시다아제효소 저해능을 나타내었다.As shown in Figure 2 below, it was found that fucoidan FUCO1 to FUCO9 of the present invention inhibit the enzymatic activity of alpha-glucosidase enzyme in a concentration-dependent manner, and fucoidan FUCO1 extracted including only the first purification step of the present invention In comparison, fucoidan FUCO2 extracted by further comprising a second purification step and fucoidan FUCO3 further comprising a second purification step and a third purification step showed excellent alpha-glucosidase enzyme inhibition ability.
또한, 본 발명의 S2 단계에서 본 발명의 중금속 흡착 조성물(BSC1 내지 BSC6)을 포함하여 후코이단을 추출하는 경우, 알긴산(alginic acid), 라미나린(laminarin) 등의 다당류, 비소 등의 중금속 성분이 제거되어 더욱 우수한 후코이단 함량을 나타냄에 따라, 알파-글루코시다아제효소 저해능 또한 상승하는 것으로 확인하였다.In addition, when extracting fucoidan including the heavy metal adsorption composition (BSC1 to BSC6) of the present invention in step S2 of the present invention, polysaccharides such as alginic acid and laminarin, and heavy metal components such as arsenic are removed. It was confirmed that as the fucoidan content became more excellent, the alpha-glucosidase enzyme inhibitory ability also increased.
[실험예3: 해조류로부터 후코이단을 추출하는 공정에 따른 비교][Experimental Example 3: Comparison of fucoidan extraction processes from seaweed]
1. 경제성 비교1. Economic comparison
본 발명의 추출 방법, 열수 추출법, 산처리 추출법 및 냉수 추출법에 따른 추출물의 수율과 추출물 100g 생산에 필요한 소모성 물품인 시약 등의 가격($1=1,000원으로 계산)을 평가하였다.The yield of the extract according to the extraction method, hot water extraction method, acid treatment extraction method, and cold water extraction method of the present invention and the price of reagents, which are consumable items required to produce 100 g of extract (calculated as $1 = 1,000 won) were evaluated.
상기 해조류는 미역귀, 톳, 모자반, 다시마, 꼬시래기 및 뜸부기를 대상으로 실시하였으며, 각 추출공정마다 3회씩 추출을 진행하였다, 그 값은 평균±표준편차로 나타내었으며, 그 결과를 하기 도 3에 나타내었다.The seaweed was tested on wakame seaweed, hijiki, kelp, seaweed, and moxa, and extraction was performed three times for each extraction process. The values were expressed as mean ± standard deviation, and the results are shown in Figure 3 below. It was.
하기 도 3에 도시된 바와 같이, 추출물의 수율은 공정마다 큰 차이를 나타내었으며, 본 발명의 추출 방법, 열수 추출법, 산처리 추출법 및 냉수 추출법의 순으로 수율이 우수함으로 확인하였다(도 3a). As shown in Figure 3 below, the yield of the extract showed significant differences depending on the process, and the yield was confirmed to be excellent in the following order: the extraction method of the present invention, the hot water extraction method, the acid treatment extraction method, and the cold water extraction method (Figure 3a).
또한, 해조류 추출물 100g을 얻기 위해 소요되는 소모성 물품(시약 등)의 가격을 공정별로 계산한 결과, 개발법은 $272이 필요하며, 이는 시판용 제품의 생산비용의 약 70% 수준이었다. 특히, 냉수 추출법과 비교 시 1/7의 비용으로 소요되어 경제성을 확인하였다(도 3b).In addition, as a result of calculating the price of consumable items (reagents, etc.) required for each process to obtain 100g of seaweed extract, the development method required $272, which was about 70% of the production cost of a commercial product. In particular, when compared to the cold water extraction method, it took 1/7 the cost, confirming economic feasibility (Figure 3b).
2. 전분분해효소 저해능 비교2. Comparison of starch degrading enzyme inhibition ability
상기 각 추출 방법에 따라 추출된 해조류 추출물의 혈당 조절 기능성을 확인하기 위하여 전분분해에 관여하는 알파-아밀레이스(α-amylase) 저해능과 포도당 생성에 관여하는 알파-글루코시다제(α-glucosidase)의 활성을 평가하여 하기 도 5에 나타내었다.In order to confirm the blood sugar control functionality of the seaweed extract extracted according to each of the above extraction methods, the inhibitory ability of alpha-amylase, which is involved in starch decomposition, and the α-glucosidase, which is involved in glucose production, were tested. The activity was evaluated and shown in Figure 5 below.
하기 도 5a에 도시된 바와 같이, 알파-아밀레이스(α-amylase) 저해능은 관찰되지 않았으나, 도 5b에 도시된 바와 같이, 추출 방법에 따라 추출물들의 알파-글루코시다제(α-glucosidase) 저해능은 크게 차이가 나타나는 것을 확인하였다.As shown in Figure 5a below, alpha-amylase (α-amylase) inhibitory ability was not observed, but as shown in Figure 5b, the alpha-glucosidase (α-glucosidase) inhibitory ability of the extracts depending on the extraction method was It was confirmed that there was a significant difference.
또한, 제조 공정별 추출물들의 α-glucosidase의 IC-50값은 본 발명의 추출방법은 0.031mg/mL, 냉수 추출법은 0.080 mg/mL, 열수추출법은 0.125 mg/mL, 시판용은 0.162 mg/mL, 항당뇨 의약품 주성분인 acarbose는 0.146 mg/mL로 측정되어, α-glucosidase 저해능은 본 발명의 추출 방법으로 추출된 해조류 추출물이 가장 우수한 것으로 확인하였다.In addition, the IC- 50 value of α-glucosidase of the extracts by manufacturing process was 0.031 mg/mL for the extraction method of the present invention, 0.080 mg/mL for the cold water extraction method, 0.125 mg/mL for the hot water extraction method, and 0.162 mg/mL for the commercially available product. Acarbose, the main ingredient of anti-diabetic drugs, was measured at 0.146 mg/mL, and it was confirmed that the seaweed extract extracted using the extraction method of the present invention had the best α-glucosidase inhibitory ability.
3. 이화학적 특성 비교3. Comparison of physicochemical properties
상기 각 추출방법의 이화학적 특성을 비교평가하기 위하여, 본 발명의 추출방법, 열수 추출법, 산처리 추출법 및 냉수 추출법에 따른 탄수화물(carbohydrate), 당(Protein), 우론산(uronic acid), 황산염(sulfate) 함량 및 분자량을 확인하였다.In order to compare and evaluate the physicochemical properties of each of the above extraction methods, carbohydrates, sugars, uronic acid, and sulfate (protein) according to the extraction method, hot water extraction method, acid treatment extraction method, and cold water extraction method of the present invention. sulfate) content and molecular weight were confirmed.
그 결과를 하기 표 4에 나타내었다.The results are shown in Table 4 below.
상기 표 4에 나타낸 바와 같이, 본 발명에 따라 추출된 해조류 추출물은 887KDa의 분자량과 18.8%의 황함량을 나타내었으며, 다른 추출공정의 경우에는 황함량이 34% 이상으로 본 발명의 추출 방법보다 높았으나, 상기에서 확인한 바와 같이 알파-글루코시다제(α-glucosidase) 저해능이 우수하지 못하는 것을 확인하였다.As shown in Table 4, the seaweed extract extracted according to the present invention had a molecular weight of 887 KDa and a sulfur content of 18.8%, and in the case of other extraction processes, the sulfur content was more than 34%, which was higher than the extraction method of the present invention. However, as confirmed above, it was confirmed that the alpha-glucosidase inhibitory ability was not excellent.
또한, 산 추출법의 경우 분자량이 77.9KDa로 가장 낮고, 황함량이 53.2%로 가장 높은데도 불구하고, 알파-글루코시다제(α-glucosidase) 저해능이 우수하지 못하는 것을 보아, 추출된 후코이단의 분자량은 추출법에 따라 차이가 나타나는 것을 알 수 있으며, 낮은 분자량과 높은 황함량은 전분분해효소 저해능을 갖도록 하는 주요 요인이 아님을 확인하였다.In addition, in the case of the acid extraction method, although the molecular weight was the lowest at 77.9 KDa and the sulfur content was the highest at 53.2%, the alpha-glucosidase inhibition ability was not excellent, so the molecular weight of the extracted fucoidan was It can be seen that differences appear depending on the extraction method, and it was confirmed that low molecular weight and high sulfur content are not the main factors for starch decomposition enzyme inhibition ability.
4. 분자량 분포 비교4. Comparison of molecular weight distribution
상기 각 추출 방법의 분자량 분포를 비교하기 위해, 본 발명의 추출방법, 열수 추출법, 산처리 추출법 및 냉수 추출법에 따른 해조류 추출물의 분자량 분포를 확인하였다,In order to compare the molecular weight distribution of each of the above extraction methods, the molecular weight distribution of the seaweed extract according to the extraction method of the present invention, hot water extraction method, acid treatment extraction method, and cold water extraction method was confirmed.
상기 분자량 분포는 RI profile로 검토하여 그 결과를 하기 도 4에 나타내었다.The molecular weight distribution was examined using RI profile, and the results are shown in Figure 4 below.
하기 도 4에 도시된 바와 같이, 본 발명의 추출 방법과, 열수 추출법, 시판용 추출물의 경우 분자량의 분포가 일정하여 유사한 분자량으로 구성되어 있음을 확인할 수 있었다.As shown in Figure 4 below, it was confirmed that the extraction method of the present invention, the hot water extraction method, and the commercially available extract had a constant molecular weight distribution and were composed of similar molecular weights.
5. 추출물의 구성 단당류 분석5. Analysis of monosaccharides in the extract
상기 각 추출 방법으로 추출된 해조류 추출물의 구성 단당류를 분석한 결과를 하기 표 5 및 6에 나타내었다. The results of analyzing the monosaccharides of the seaweed extract extracted by each of the above extraction methods are shown in Tables 5 and 6 below.
(Ramnose)rhamnose
(Ramnose)
(Ramnose)rhamnose
(Ramnose)
상기 표 5 및 6에 나타낸 바와 같이, 본 발명의 추출 방법에 따른 해조류 추출물은 다른 방법의 추출물과 비교하여, 만노스(mannose)의 비율이 상대적으로 높게(20.2%) 확인되었다.As shown in Tables 5 and 6, the seaweed extract according to the extraction method of the present invention was confirmed to have a relatively high mannose ratio (20.2%) compared to extracts from other methods.
상기 만노스는 당의 일종이나, 극소량만 대사에 사용되며, 대부분 체외로 배출되기 때문에 혈당에 영향을 주지 않아, 당뇨환자에게 안전한 성분이다.The mannose is a type of sugar, but only a very small amount is used in metabolism, and since most of it is excreted outside the body, it does not affect blood sugar levels, making it a safe ingredient for diabetic patients.
[실험예4: 기호성 평가][Experimental Example 4: Palatability evaluation]
본 발명에 따라 추출된 후코이단 FUCO1 내지 FUCO9에 대해 기호성 평가를 진행하였다. 후코이단 FUCO1 내지 FUCO9이 함유된 차(茶)로 제조한 이후, 성인남녀 20명에게 제공한 이후, 맛 및 향에 대한 평가를 요청하였다. A palatability evaluation was conducted on fucoidan FUCO1 to FUCO9 extracted according to the present invention. After manufacturing tea containing fucoidan FUCO1 to FUCO9, it was provided to 20 adult men and women, and evaluation of taste and aroma was requested.
평가 점수는 각 항목 당 1 내지 10점으로 평가를 요청하였으며, 평가 결과는 평균 점수로 환산하여 나타내었다. 상기 지수는 그 숫자가 높을수록 기호도가 높은 것이다.Evaluation scores were requested from 1 to 10 points for each item, and the evaluation results were converted into average scores. The higher the number, the higher the preference for the index.
(단위: 지수)(Unit: index)
상기 표 7를 참조하면, 본 발명의 제1 정제 단계만 포함하여 추출된 후코이단 FUCO1에 비해, 제2 정제 단계를 더 포함하여 추출된 후코이단 FUCO2와 제2 정제 단계 및 제3 정제 단계를 더 포함하는 후코이단 FUCO3에서 우수한 기호도를 나타냄을 확인하었다.Referring to Table 7, compared to fucoidan FUCO1 extracted including only the first purification step of the present invention, fucoidan FUCO2 extracted further including a second purification step and further comprising a second purification step and a third purification step It was confirmed that fucoidan FUCO3 showed excellent preference.
또한, 본 발명의 S2 단계에서 본 발명의 중금속 흡착 조성물(BSC1 내지 BSC6)을 포함하여 후코이단을 추출하는 경우에 천연 추출물로 인해 떨어지는 기호도를 상승시키는 것으로 확인하였다.In addition, it was confirmed that when extracting fucoidan including the heavy metal adsorption composition (BSC1 to BSC6) of the present invention in step S2 of the present invention, the preference level lowered due to the natural extract was increased.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims are also possible. falls within the scope of rights.
Claims (7)
2) 상기 1) 단계의 전처리된 해조류를 칼슘염 수용액과 혼합하는 혼합단계;
3) 상기 2) 단계의 교반된 혼합물을 원심분리시켜 감압 여과하는 제1 정제 단계;
4) 상기 3) 단계의 여과된 혼합물을 40%로 희석된 에탄올 용액에 혼합하여 상기 혼합물에 존재하는 라미나린(laminarin)을 침전시키는 단계;
5) 상기 4) 단계의 침전물을 원심분리시켜 상등액을 수득하는 제2 정제 단계;
6) 상기 5) 단계의 상등액을 알코올 용액에 침전시키는 단계;
7) 상기 6) 단계의 침전물을 원심분리시켜 상등액을 제거하는 제3 정제 단계; 및
8) 상기 7) 단계의 상등액이 제거되고 남은 침전물을 건조시켜 후코이단(Fucoidan)을 획득하는 단계를 포함하는 혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법으로,
상기 칼슘염 수용액은 중금속 흡착 조성물을 더 포함하며,
상기 중금속 흡착 조성물은 타임(Thymus vulgaris) 추출물, 캐롭(Ceratonia siliqua (L.) Taub.) 추출물 및 도랭이 사초(Carex nubigena var. albata) 추출물을 포함하는 것인
혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법.1) Pretreatment step of drying and desalting seaweed;
2) a mixing step of mixing the seaweed pretreated in step 1) with an aqueous calcium salt solution;
3) a first purification step of centrifuging the stirred mixture of step 2) and filtering it under reduced pressure;
4) mixing the filtered mixture of step 3) with an ethanol solution diluted to 40% to precipitate laminarin present in the mixture;
5) a second purification step of centrifuging the precipitate from step 4) to obtain a supernatant;
6) Precipitating the supernatant of step 5) in an alcohol solution;
7) a third purification step of centrifuging the precipitate from step 6) to remove the supernatant; and
8) A method of extracting fucoidan capable of controlling blood sugar from seaweed, comprising the step of obtaining fucoidan by removing the supernatant of step 7) and drying the remaining sediment,
The calcium salt aqueous solution further includes a heavy metal adsorption composition,
The heavy metal adsorption composition includes thyme (Thymus vulgaris) extract, carob (Ceratonia siliqua (L.) Taub.) extract, and sedge sedge (Carex nubigena var. albata) extract.
A method of extracting fucoidan, which can control blood sugar levels, from seaweed.
상기 칼슘염 수용액은 염화칼슘(CaCl2) 수용액, 탄산칼슘(CaCO3) 수용액, 수산화칼슘(Ca(OH)-2) 및 이들의 혼합으로 이루어진 군으로부터 선택되는
혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법.According to clause 1,
The calcium salt aqueous solution is selected from the group consisting of calcium chloride (CaCl 2 ) aqueous solution, calcium carbonate (CaCO 3 ) aqueous solution, calcium hydroxide (Ca(OH) -2 ), and mixtures thereof.
A method of extracting fucoidan, which can control blood sugar levels, from seaweed.
상기 해조류는 미역귀, 톳, 모자반, 다시마, 꼬시래기, 뜸부기 및 이들의 혼합으로 이루어진 군으로부터 선택되는
혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법.According to clause 1,
The seaweed is selected from the group consisting of seaweed, hijiki, moba, kelp, seaweed, seaweed, and mixtures thereof.
A method of extracting fucoidan, which can control blood sugar levels, from seaweed.
상기 후코이단(Fucoidan)은 600 내지 900KDa의 분자량을 나타내는 것인
혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법.According to clause 1,
The fucoidan has a molecular weight of 600 to 900 KDa.
A method of extracting fucoidan, which can control blood sugar levels, from seaweed.
상기 후코이단(Fucoidan)은 전분분해효소 저해능을 통해, 혈당 조절 효과를 나타내는 것으로,
상기 전분분해효소는 알파-글루코시다제(α-glucosidase)를 포함하는 것인
혈당 조절이 가능한 후코이단을 해조류로부터 추출하는 방법.According to clause 4,
The fucoidan exhibits a blood sugar control effect through starch-degrading enzyme inhibition,
The starch-decomposing enzyme includes alpha-glucosidase (α-glucosidase).
A method of extracting fucoidan, which can control blood sugar levels, from seaweed.
당뇨병 예방 및 개선용 식품 조성물.Containing fucoidan extracted according to any one of claims 1 to 5
Food composition for preventing and improving diabetes.
당뇨병 예방 및 치료용 약학 조성물.Containing fucoidan extracted according to any one of claims 1 to 5
Pharmaceutical composition for preventing and treating diabetes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210021101A KR102660778B1 (en) | 2021-02-17 | 2021-02-17 | Method for extracting fucoidan for glycemic control from seaweed |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210021101A KR102660778B1 (en) | 2021-02-17 | 2021-02-17 | Method for extracting fucoidan for glycemic control from seaweed |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220117578A KR20220117578A (en) | 2022-08-24 |
KR102660778B1 true KR102660778B1 (en) | 2024-04-24 |
Family
ID=83111870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210021101A KR102660778B1 (en) | 2021-02-17 | 2021-02-17 | Method for extracting fucoidan for glycemic control from seaweed |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102660778B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116076595B (en) * | 2023-02-24 | 2024-07-23 | 国健药业(深圳)集团有限公司 | Kaqi flower-pedicle-ma compound extract, preparation method and lipid-reducing health-care tea |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9927984B2 (en) | 2015-10-14 | 2018-03-27 | Samsung Electronics Co., Ltd. | Electronic system with interface control mechanism and method of operation thereof |
KR101777673B1 (en) | 2015-10-16 | 2017-09-12 | 주식회사 비티진 | Preparation method of ginsenoside-Rd using an enzyme |
-
2021
- 2021-02-17 KR KR1020210021101A patent/KR102660778B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
T. Vinoth Kumar, et al. Int J Biol Macromol. 72:1044-1047(2015)* |
Also Published As
Publication number | Publication date |
---|---|
KR20220117578A (en) | 2022-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100935847B1 (en) | Manufacturing method for the slice of red ginseng | |
KR101817055B1 (en) | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities | |
KR20180137174A (en) | Health supplementing food for enhancing hair restoration, alleviating and improving hair loss | |
KR20150040392A (en) | undiluted stevia liquid and the berages, and its manufacturing method | |
KR101717431B1 (en) | Healthy food composition having anti-obesity and anti-diabetic activities | |
Ferrara | Nutritional and pharmacological properties of Tamarindus indica L | |
KR102660778B1 (en) | Method for extracting fucoidan for glycemic control from seaweed | |
KR20090098024A (en) | The method of manufacturing of medicinal wine | |
KR20200014992A (en) | An anti-obesity composition comprising Gelidium amansii extract and Salicornia europaea extract | |
CN105124077A (en) | Passion fruit and tomato tea bag | |
KR20070089309A (en) | The preparation method of concentrated material of gelidium sp. showing antibacterial, anti-oxidative and antitumor activities and the functional food composition comprising the same | |
KR20110056908A (en) | Composition of mixed herb medicine for leached tea | |
KR101768612B1 (en) | Food composition for improving liver function and method of health tea using thereof | |
KR100884844B1 (en) | Emotional Tea with spicy, sweety Collagen Apple Vita Green Tea | |
KR101473342B1 (en) | Method of preparing for semi-dried muk | |
KR101962893B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
CN111184809A (en) | Food, health-care product or medicine composition for clearing and moistening throat and preparation method thereof | |
CN104938730A (en) | Passion fruit sweet tea | |
KR102585767B1 (en) | Method for extracting polysaccharides with excellent blood sugar control effect from red ginseng | |
CN103005121A (en) | Low-sugar preserved Chinese chestnut and preparation method thereof | |
KR102636801B1 (en) | Composition comprising extract of pelvetia siliquosa for treating or preventing diabetes and method for preparing the same | |
KR102489041B1 (en) | Production method of low salt napa cabbage kimchi using functional spice | |
KR102367647B1 (en) | Production method of egg having anti-oxidant ability and blood circulation ability using the feed composition for chicken including rhus verniciflua extract, and egg produced by the same method | |
KR20190007325A (en) | Health functional onion beverage and its manufacturing method | |
KR101060307B1 (en) | Diabetic treatment or prevention composition comprising sun salt and perilla extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |